Abstract
The management of early Parkinson's disease (PD) involves the treatment of motor symptoms and, increasingly, non-motor symptoms. Given the fast pace of clinical research in PD, clinicians are faced with the challenge of integrating the latest findings into the ongoing care of individual PD patients. Part 1 of this 2-part article reviews motor symptom efficacy data for the newest PD treatment options, as well as for established therapies. Safety and tolerability data are also reviewed. Part 2 of the article reviews key findings relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms.
Original language | English (US) |
---|---|
Pages (from-to) | 193-205 |
Number of pages | 13 |
Journal | European Neurology |
Volume | 61 |
Issue number | 4 |
DOIs | |
State | Published - Mar 2009 |
Keywords
- Dopamine agonists
- Levodopa
- Monoamine oxidase B inhibitors
- Parkinson's disease
ASJC Scopus subject areas
- Clinical Neurology
- Neurology